Persistent EBV infection has been shown to be controlled by the human adaptive immune response, particularly by CD8+ EBV-specific CTLs (126).These EBV antigen-specific CD8+ responses emerge during the first year following infection (127). This evidence concerns the gene CD8A and Epstein-Barr virus infection.